• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to project page

2021 Fiscal Year Final Research Report

Development of therapy for hemolytic uremic syndrome with a focus on microRNA/high mobility group box-1 signaling

Research Project

  • PDF
Project/Area Number 19K17748
Research Category

Grant-in-Aid for Early-Career Scientists

Allocation TypeMulti-year Fund
Review Section Basic Section 53040:Nephrology-related
Research InstitutionFukushima Medical University

Principal Investigator

Ryo Maeda  福島県立医科大学, 医学部, 助教 (60792025)

Project Period (FY) 2019-04-01 – 2022-03-31
Keywords溶血性尿毒症症候群 / HMGB1 / miRNA
Outline of Final Research Achievements

Typical (Shiga toxin-producing Escherichia coli-associated) hemolytic uremic syndrome (HUS) is the leading cause of acute kidney injury in children, and no specific treatment methods have been established. In HUS-model mice treated with Shiga toxin 2 (Stx2) and lipopolysaccharide (LPS), we conducted array analyses to identify changes in the expression of target microRNAs involved in high mobility group box-1 signaling. We focused on dual Specificity Phosphatase 8 (DUSP8), a miR-21-related mRNA with a large magnitude fold-change. DUSP8 expression was higher in the kidneys of HUS-model mice than in the kidneys of healthy mice. Proximal convoluted tubule (TKPTS) and collecting duct cells (M-1) treated with Stx2 and LPS in vitro showed no appreciable changes. A possible reason is the use of immortalized cells. Thus, we will use primary mouse renal tubular cells in reexaminations.

Free Research Field

腎臓病学

Academic Significance and Societal Importance of the Research Achievements

HUSモデルマウスとmiRNAとの関与を検討した報告は少ない。本研究ではmiRNAのmiR-21に関連するmRNAのDUSP8がHUSの病態に関与している可能性が示唆された。さらなる検証を進めることでHUSとmiR-21やDUSP8との関連を明らかにでき、病態が解明されることで未だ特異的治療法のないHUSの治療法が確立しうるため、本研究の学術的意義は高い。

URL: 

Published: 2023-01-30  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi